This trial is an open-label phase 1/2a trial, designed to evaluate the safety of the retinal progenitor cells injected into the vitreous cavity at 2 different dosage levels in patients with late-stage retinitis pigmentosa.
Today 4 patients have received intra-vitreal cell injections. Total study participants will be 16 patients, followed for 12 months.
First results will be available in 12/24 months. As soon as results will become available we will post an update. Dr Badala keeps collaborating with Researchers at University of California Los Angeles (UCLA)